Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 8-K Current report
- 2.4 EX-2.4
- 3.1 EX-3.1
- 3.2 EX-3.2
- 3.3 EX-3.3
- 3.4 EX-3.4
- 3.5 EX-3.5
- 3.6 EX-3.6
- 10.1 EX-10.1
- 10.2 EX-10.2
- 10.3 EX-10.3
- 10.6 EX-10.6
- 10.7 EX-10.7
- 10.8 EX-10.8
- 10.9 EX-10.9
- 10.10 EX-10.10
- 10.11 EX-10.11
- 10.12 EX-10.12
- 10.13 EX-10.13
- 10.14 EX-10.14
- 10.15 EX-10.15
- 10.16 EX-10.16
- 10.17 EX-10.17
- 10.18 EX-10.18
- 10.19 EX-10.19
- 10.20 EX-10.20
- 10.21 EX-10.21
- 10.22 EX-10.22
- 14.1 EX-14.1
- 99.1 Qualigen Therapeutics Announces Merger Closing
QLGN similar filings
- 11 Jun 20 Departure of Directors or Certain Officers
- 3 Jun 20 Changes in Registrant's Certifying Accountant
- 29 May 20 Changes in Registrant's Certifying Accountant
- 29 May 20 Qualigen Therapeutics Announces Merger Closing
- 19 May 20 Termination of a Material Definitive Agreement
- 14 May 20 Ritter Pharmaceuticals, Inc. Announces Adjournment of its Special Meeting
- 11 May 20 Other Events
Filing view
External links
Exhibit 3.4
RITTER PHARMACEUTICALS, INC.
CERTIFICATE OF AMENDMENT
TO
THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
Ritter Pharmaceuticals, Inc. (the “Corporation”), a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that:
1. | The name of the corporation is Ritter Pharmaceuticals, Inc. | |
2. | This Certificate of Amendment (the “Certificate of Amendment”) amends the provisions of the Corporation’s Certificate of Incorporation first filed with the Secretary of State on September 16, 2008, as amended (the “Certificate of Incorporation”). | |
3. | Article I of the Certificate of Incorporation is hereby amended and restated to read in its entirety as follows: |
“ARTICLE I
NAME
The name of the Corporation is Qualigen Therapeutics, Inc. (the “Corporation”).”
4. | This amendment was duly adopted in accordance with the provisions of Section 242 of the DGCL. | |
5. | This Certificate of Amendment shall become effective at 8:10 p.m., Eastern Time, on May 22, 2020, and no sooner. |
IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its Chief Executive Officer on this 22nd day of May 2020.
RITTER PHARMACEUTICALS, INC. | ||
By | /s/ Andrew Ritter | |
Name: | Andrew Ritter | |
Title: | Chief Executive Officer |